Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
The filing is for the combination in MET-driven EGFR-mutated non-small cell lung cancer. It is supported by the SAFFRON Phase III trial, which showed improvements in progression-free and overall survival, according to the company.
Hutchmed (China) said the application is for MET-driven EGFR-mutated lung cancer.
HUTCHMED (China) Ltd HKEX:13
HUTCHMED said it submitted a US NDA for ORPATHYS plus TAGRISSO in MET-driven EGFR-mutated lung cancer.